Overview

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, 2-part, sequential, single ascending dose study. Part 1 is planned as 6 sequential escalation treatment groups. Part 2 is a randomized, placebo-controlled, two-period sequential pharmacodynamic (PD) arm.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.